ESSEX BIO-TECH (01061) issues profit warning, expecting a decrease of about 30% in mid-term profit compared to the previous year.

ESSEX BIO-TECH (01061) announces that the group is expecting a decrease of approximately 10% in revenue and 30% in profit for the six months ending June 30, 2026 (mid-2026 period) compared to the same period in 2025, with revenue around 877 million Hong Kong dollars and profit around 163 million Hong Kong dollars. This is mainly due to the increase in value-added tax borne by the group following the implementation of the new value-added tax law in China. Despite the above situation, the group maintains a strong cash flow and financial position to meet its business needs. As of June 30, 2026, the group's cash and cash equivalents are approximately 807 million Hong Kong dollars.